MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Severe Aplastic Anemia
Acquired Amegakaryocytic Thrombocytopenia
Acquired Pure Red Cell Aplasia
Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: Rituximab
DRUG: Rabbit ATG
DRUG: Cyclophosphamide
DRUG: Fludarabine
RADIATION: Total Body Irradiation
BIOLOGICAL: Cell Infusion
DRUG: Post-Transplant G-CSF
DRUG: Tacrolimus
DRUG: Mycophenolate Mofetil

Sponsor

Masonic Cancer Center, University of Minnesota